{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:46:46Z","timestamp":1791334006983,"version":"4.3.1"},"reference-count":53,"publisher":"Oxford University Press (OUP)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Degos disease is a lethal small vessel angiopathy targeting the skin, gastrointestinal tract, and central nervous system, potentially developing in the setting of known autoimmune disease, although forme fruste primary variants exist. Its pathogenetic basis is unknown.<\/jats:p>\n               <jats:p>Four cases of Degos disease were encountered in archival material, representing 2 men, ages 38 and 43 years, and 2 females, ages 48 and 2 years; 3 patients died of disease. All had characteristic skin lesions with gastrointestinal involvement; other affected organs included brain in one and pericardium and pleura in another. Skin biopsies showed pauci-inflammatory thrombogenic microangiopathy with endothelial cell injury. Extracutaneous organs demonstrated fibromucinous occlusive arteriopathy. Prominent vascular C5b-9 was seen in the skin, gastrointestinal tract, and brain. All cases had evidence of high expression of interferon-\u03b1 (based on tissue expression of MXA, a type I interferon-inducible protein), endothelial tubuloreticular inclusions, and an interferon gene signature in peripheral blood mononuclear cells. The MXA expression paralleled the pattern of C5b-9 deposition.<\/jats:p>\n               <jats:p>Degos disease is a distinct vascular injury syndrome whereby a dysregulated interferon-\u03b1 response in concert with membranolytic attack complex deposition may contribute to the unique vascular changes. Understanding the pathophysiology of the disease process could lead to more directed therapies, including terminal complement inhibition with agents such as eculizumab.<\/jats:p>","DOI":"10.1309\/ajcp66qimfarlzki","type":"journal-article","created":{"date-parts":[[2011,3,16]],"date-time":"2011-03-16T23:39:51Z","timestamp":1300318791000},"page":"599-610","source":"Crossref","is-referenced-by-count":107,"title":["Degos Disease"],"prefix":"10.1093","volume":"135","author":[{"given":"Cynthia M.","family":"Magro","sequence":"first","affiliation":[{"name":"1Division of Dermatopathology, Department of Pathology and Laboratory Medicine, Weill Cornell College of Cornell University, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan C.","family":"Poe","sequence":"additional","affiliation":[{"name":"2Department of Immunology, Duke University Medical Center, Durham, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connie","family":"Kim","sequence":"additional","affiliation":[{"name":"3New York University, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee","family":"Shapiro","sequence":"additional","affiliation":[{"name":"4Department of Rheumatology, Albany Medical College, Albany, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard","family":"Nuovo","sequence":"additional","affiliation":[{"name":"5Pathology, Ohio State University, Columbus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary K.","family":"Crow","sequence":"additional","affiliation":[{"name":"6Division of Rheumatology, Hospital for Special Surgery, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanick J.","family":"Crow","sequence":"additional","affiliation":[{"name":"7Genetic Medicine, University of Manchester, Manchester Academic Health Science Centre, Central Manchester Foundation Trust University Hospitals, Manchester, England"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2011,4,1]]},"reference":[{"key":"2023011909494606100_b1-1350599","first-page":"269","article-title":"2 families with malignant atrophic papulosis (Degos disease) [in Dutch]","volume":"132","author":"Beljaards","year":"1988","journal-title":"Ned Tijdschr Geneeskd"},{"key":"2023011909494606100_b2-1350599","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1001\/archderm.1969.01610290059012","article-title":"Progressive systemic sclerosis with malignant atrophic papulosis","volume":"100","author":"Durie","year":"1969","journal-title":"Arch Dermatol"},{"key":"2023011909494606100_b3-1350599","first-page":"414","article-title":"Diabetes mellitus and Degos disease [published correction appears in Bratisl Lek Listy. 2008;109:533]","volume":"109","author":"Fernandez-Flores","year":"2008","journal-title":"Bratisl Lek Listy"},{"key":"2023011909494606100_b4-1350599","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S1085-5629(05)80004-5","article-title":"Degos syndrome: malignant atrophic papulosis","volume":"14","author":"Snow","year":"1995","journal-title":"Semin Dermatol"},{"key":"2023011909494606100_b5-1350599","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1159\/000248781","article-title":"Skin lesions resembling malignant atrophic papulosis in lupus erythematosus","volume":"175","author":"Doutre","year":"1987","journal-title":"Dermatologica"},{"key":"2023011909494606100_b6-1350599","first-page":"133","article-title":"Lethal systemic Degos disease with prominent cardio-pulmonary involvement","volume":"29","author":"Notash","year":"2008","journal-title":"Saudi Med J"},{"key":"2023011909494606100_b7-1350599","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.jaad.2003.11.063","article-title":"Is Degos\u2019 disease a clinical and histological end point rather than a specific disease?","volume":"50","author":"High","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"2023011909494606100_b8-1350599","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1111\/j.1365-2230.2008.02953.x","article-title":"Wegener\u2019s granulomatosis: a new entity in the growing differential diagnosis of Degos\u2019 disease","volume":"34","author":"Guhl","year":"2009","journal-title":"Clin Exp Dermatol"},{"key":"2023011909494606100_b9-1350599","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S0190-9622(97)80407-0","article-title":"Lesions resembling malignant atrophic papulosis in a patient with dermatomyositis","volume":"36","author":"Tsao","year":"1997","journal-title":"J Am Acad Dermatol"},{"key":"2023011909494606100_b10-1350599","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2340\/00015555-0068","article-title":"A fatal case of malignant atrophic papulosis (Degos\u2019 disease) in a man with factor V Leiden mutation and lupus anticoagulant","volume":"86","author":"Hohwy","year":"2006","journal-title":"Acta Derm Venereol"},{"issue":"3 pt 1","key":"2023011909494606100_b11-1350599","first-page":"480","article-title":"Malignant atrophic papulosis (Degos\u2019 disease) involving three generations of a family","volume":"37","author":"Katz","year":"1997","journal-title":"J Am Acad Dermatol"},{"key":"2023011909494606100_b12-1350599","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpn.2010.06.003","article-title":"Infantile neurological Degos disease [published online ahead of print July 24, 2010]","author":"Yeo","journal-title":"Eur J Paediatr Neurol"},{"key":"2023011909494606100_b13-1350599","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/j.1600-0560.2008.01171.x","article-title":"Fulminant and accelerated presentation of dermatomyositis in two previously healthy young adult males: a potential role for endotheliotropic viral infection","volume":"36","author":"Magro","year":"2009","journal-title":"J Cutan Pathol"},{"key":"2023011909494606100_b14-1350599","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1034\/j.1600-0560.2002.291005.x","article-title":"Immunoglobulin A\u2013associated lymphocytic vasculopathy: a clinicopathologic study of eight patients","volume":"29","author":"Crowson","year":"2002","journal-title":"J Cutan Pathol"},{"key":"2023011909494606100_b15-1350599","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/j.1600-0560.2009.01443.x","article-title":"The phenotypic profile of dermatomyositis and lupus erythematosus: a comparative analysis [published online ahead of print November 4, 2009]","volume":"37","author":"Magro","year":"2010","journal-title":"J Cutan Pathol"},{"key":"2023011909494606100_b16-1350599","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1111\/j.1600-0560.1997.tb01458.x","article-title":"The immunofluorescent profile of dermatomyositis: a comparative study with lupus erythematosus.","volume":"24","author":"Magro","year":"1997","journal-title":"J Cutan Pathol"},{"key":"2023011909494606100_b17-1350599","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0046-8177(96)90132-X","article-title":"The role of microvascular injury in the pathogenesis of cutaneous lesions of dermatomyositis","volume":"27","author":"Crowson","year":"1996","journal-title":"Hum Pathol"},{"key":"2023011909494606100_b18-1350599","doi-asserted-by":"crossref","first-page":"3958","DOI":"10.1002\/art.20798","article-title":"Coordinate overexpression of interferon-alpha\u2013induced genes in systemic lupus erythematosus","volume":"50","author":"Kirou","year":"2004","journal-title":"Arthritis Rheum"},{"key":"2023011909494606100_b19-1350599","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1046\/j.0303-6987.2003.0143.x","article-title":"Parvoviral infection of endothelial cells and stromal fibroblasts: a possible pathogenetic role in scleroderma","volume":"31","author":"Magro","year":"2004","journal-title":"J Cutan Pathol"},{"issue":"5 pt 1","key":"2023011909494606100_b20-1350599","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/0190-9622(95)91843-4","article-title":"Absence of antiphospholipid and anti\u2013endothelial cell antibodies in malignant atrophic papulosis: a study of 15 cases","volume":"33","author":"Assier","year":"1995","journal-title":"J Am Acad Dermatol"},{"key":"2023011909494606100_b21-1350599","first-page":"581","article-title":"Sera from patients with systemic lupus erythematosus reactive with human endothelial cells","volume":"8","author":"Shingu","year":"1981","journal-title":"J Rheumatol"},{"key":"2023011909494606100_b22-1350599","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/0090-1229(92)90232-D","article-title":"Antibodies to endothelial cells in primary vasculitides mediate in vitro endothelial cytotoxicity in the presence of normal peripheral blood mononuclear cells","volume":"63","author":"del Papa","year":"1992","journal-title":"Clin Immunol Immunopathol"},{"key":"2023011909494606100_b23-1350599","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/j.1365-2249.1994.tb06136.x","article-title":"Antiendothelial cell antibodies can be cytotoxic to endothelial cells without cytokine pre-stimulation and correlate with ELISA antibody measurement in Kawasaki disease","volume":"98","author":"Kaneko","year":"1994","journal-title":"Clin Exp Immunol"},{"key":"2023011909494606100_b24-1350599","first-page":"462","article-title":"Antiendothelial cell antibodies in scleroderma correlate with severe digital ischemia and pulmonary arterial hypertension","volume":"25","author":"Negi","year":"1998","journal-title":"J Rheumatol"},{"key":"2023011909494606100_b25-1350599","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1309\/8HVCMJMYNPUQPBD2","article-title":"The assessment of anti\u2013endothelial cell antibodies in scleroderma-associated pulmonary fibrosis: a study of indirect immunofluorescent and Western blot analysis in 49 patients with scleroderma","volume":"120","author":"Wusirika","year":"2003","journal-title":"Am J Clin Pathol"},{"key":"2023011909494606100_b26-1350599","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1073\/pnas.72.5.1687","article-title":"Neoantigens of the membrane attack complex of human complement","volume":"72","author":"Kolb","year":"1975","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2023011909494606100_b27-1350599","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1126\/science.2425429","article-title":"The ninth component of complement and the pore-forming protein (perforin 1) from cytotoxic T cells: structural, immunological, and functional similarities","volume":"233","author":"Young","year":"1986","journal-title":"Science"},{"key":"2023011909494606100_b28-1350599","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1056\/NEJMoa031688","article-title":"Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria","volume":"350","author":"Hillmen","year":"2004","journal-title":"N Engl J Med"},{"key":"2023011909494606100_b29-1350599","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1182\/blood-2005-02-0564","article-title":"Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria","volume":"106","author":"Hill","year":"2005","journal-title":"Blood"},{"key":"2023011909494606100_b30-1350599","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/j.1600-6143.2008.02451.x","article-title":"The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection","volume":"9","author":"Locke","year":"2009","journal-title":"Am J Transplant"},{"key":"2023011909494606100_b31-1350599","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.2215\/CJN.01090209","article-title":"Complement inhibitor eculizumab in atypical hemolytic uremic syndrome","volume":"4","author":"Mache","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"2023011909494606100_b32-1350599","first-page":"1017","article-title":"Eculizumab (Alexion)","volume":"3","author":"Kaplan","year":"2002","journal-title":"Curr Opin Investig Drugs"},{"key":"2023011909494606100_b33-1350599","doi-asserted-by":"crossref","first-page":"28419","DOI":"10.1074\/jbc.R110.145839","article-title":"Dynamin-like MXA GTPase: structural insights into oligomerization and implications for antiviral activity [published online ahead of print June 10, 2010]","volume":"285","author":"Haller","year":"2010","journal-title":"J Biol Chem"},{"key":"2023011909494606100_b34-1350599","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/ana.20464","article-title":"Interferon-alpha\/beta\u2013mediated innate immune mechanisms in dermatomyositis","volume":"57","author":"Greenberg","year":"2005","journal-title":"Ann Neurol"},{"key":"2023011909494606100_b35-1350599","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/art.27182","article-title":"Genetic variation at the IRF7\/PHRF1 locus is associated with autoantibody profile and serum interferon-alpha activity in lupus patients","volume":"62","author":"Salloum","year":"2010","journal-title":"Arthritis Rheum"},{"key":"2023011909494606100_b36-1350599","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1002\/art.23613","article-title":"Association of the IRF5 risk haplotype with high serum interferon-alpha activity in systemic lupus erythematosus patients","volume":"58","author":"Niewold","year":"2008","journal-title":"Arthritis Rheum"},{"key":"2023011909494606100_b37-1350599","doi-asserted-by":"crossref","first-page":"2818","DOI":"10.1002\/art.23728","article-title":"The PTPN22 C1858T polymorphism is associated with skewing of cytokine profiles toward high interferon-alpha activity and low tumor necrosis factor alpha levels in patients with lupus","volume":"58","author":"Kariuki","year":"2008","journal-title":"Arthritis Rheum"},{"key":"2023011909494606100_b38-1350599","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jaad.2005.02.031","article-title":"Cutaneous necrosis after injection of polyethylene glycol-modified interferon alpha","volume":"53","author":"Dalmau","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"2023011909494606100_b39-1350599","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1053\/sarh.2002.34606","article-title":"Interferon-induced Raynaud\u2019s syndrome","volume":"32","author":"Schapira","year":"2002","journal-title":"Semin Arthritis Rheum"},{"key":"2023011909494606100_b40-1350599","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/01.inf.0000050240.76744.f3","article-title":"Severe Raynaud\u2019s phenomenon with chronic hepatitis C disease treated with interferon","volume":"22","author":"Iorio","year":"2003","journal-title":"Pediatr Infect Dis J"},{"key":"2023011909494606100_b41-1350599","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1023\/A:1026586629166","article-title":"Interferon-alpha induced Raynaud\u2019s syndrome","volume":"11","author":"Kruit","year":"2000","journal-title":"Ann Oncol"},{"key":"2023011909494606100_b42-1350599","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1080\/08916930903002479","article-title":"Premature vascular damage in systemic lupus erythematosus","volume":"42","author":"Kaplan","year":"2009","journal-title":"Autoimmunity"},{"key":"2023011909494606100_b43-1350599","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.clim.2009.07.002","article-title":"Adaptive immunity and atherosclerosis [published online ahead of print July 26, 2009]","volume":"134","author":"Andersson","year":"2010","journal-title":"Clin Immunol"},{"key":"2023011909494606100_b44-1350599","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1161\/CIRCULATIONAHA.107.697789","article-title":"Synergistic proinflammatory effects of the antiviral cytokine interferon-alpha and toll-like receptor 4 ligands in the atherosclerotic plaque","volume":"116","author":"Niessner","year":"2007","journal-title":"Circulation"},{"key":"2023011909494606100_b45-1350599","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1111\/j.1572-0241.1998.00701.x","article-title":"Retinal complications and plasma C5a levels during interferon alpha therapy for chronic hepatitis C","volume":"93","author":"Sugano","year":"1998","journal-title":"Am J Gastroenterol"},{"key":"2023011909494606100_b46-1350599","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1007\/BF02088139","article-title":"Interferon-alpha 2a increases serum concentration of hyaluronic acid and type III procollagen aminoterminal propeptide in patients with chronic hepatitis B virus infection","volume":"39","author":"Z\u00f6hrens","year":"1994","journal-title":"Dig Dis Sci"},{"key":"2023011909494606100_b47-1350599","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1034\/j.1600-0404.2000.00013.x","article-title":"Interferon-alpha2a effects on complement activation and regulation in MS patients","volume":"101","author":"Myhr","year":"2000","journal-title":"Acta Neurol Scand"},{"key":"2023011909494606100_b48-1350599","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1002\/art.21031","article-title":"Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease","volume":"52","author":"Kirou","year":"2005","journal-title":"Arthritis Rheum"},{"key":"2023011909494606100_b49-1350599","first-page":"1227","article-title":"Parvoviral infection of endothelial cells and its possible role in vasculitis and autoimmune diseases","volume":"29","author":"Magro","year":"2002","journal-title":"J Rheumatol"},{"key":"2023011909494606100_b50-1350599","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1034\/j.1600-0560.2000.027010505.x","article-title":"A causal role for parvovirus B19 infection in adult dermatomyositis and other autoimmune syndromes","volume":"27","author":"Crowson","year":"2000","journal-title":"J Cutan Pathol"},{"key":"2023011909494606100_b51-1350599","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1111\/j.1365-2133.2005.06515.x","article-title":"Parvovirus B19 and systemic sclerosis [letter]","volume":"152","author":"Ferri","year":"2005","journal-title":"Br J Dermatol"},{"key":"2023011909494606100_b52-1350599","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.arcmed.2009.09.002","article-title":"Human parvovirus b19 infection in patients with coronary atherosclerosis","volume":"40","author":"Liu","year":"2009","journal-title":"Arch Med Res"},{"key":"2023011909494606100_b53-1350599","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1159\/000277431","article-title":"Parvovirus b19 DNA is commonly harboured in human skin","volume":"220","author":"Bonvicini","year":"2010","journal-title":"Dermatology"}],"container-title":["American Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajcp\/article-pdf\/135\/4\/599\/48770025\/ajcp_135_4_599.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajcp\/article-pdf\/135\/4\/599\/48770025\/ajcp_135_4_599.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T11:34:25Z","timestamp":1674128065000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajcp\/article\/135\/4\/599\/1761081"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4,1]]},"references-count":53,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2011,4,1]]},"published-print":{"date-parts":[[2011,4,1]]}},"URL":"https:\/\/doi.org\/10.1309\/ajcp66qimfarlzki","relation":{},"ISSN":["1943-7722","0002-9173"],"issn-type":[{"value":"1943-7722","type":"electronic"},{"value":"0002-9173","type":"print"}],"subject":[],"published-other":{"date-parts":[[2011,4,1]]},"published":{"date-parts":[[2011,4,1]]}}}